title: [The additive antiproteinuric effect of Enalapril and Losartan to normotensive patients with pathology proteinuria].
abstract: The proteinuria is frequently the initial insult to the kidney and it usually followed by a progressive decline in the glomerular filtration rate. The angiotensin II mediate by glomerular permeselective function via the opening of large pores after elevations in transmembrane pressure and by acting on the glomerular pressure, too. There is evidence that angiotensin-converting enzyme inhibitors alone or with the angiotensin receptor-blockade may improve the glomerular size-selective function and the hemodynamic intrarenal accounted output of plasma proteins. We evaluated the Enalapril action only in two progressive doses (stage 1: 0.2 mg/kg/day and stage 2: 0.4 mg/kg/per day, respectively) and then we evaluated the combinated treatment (stage 3) with Enalapril (0.2 mg/kg/per day) + Losartan (0.8 mg/kg/day) in thirteen patients (2 female/ 11 male, mean age 12 yrs, r: 10y-16y) normotensive with middle or heavy proteinuria and normal glomerular filtration rate. The study lasted six months. In the three stages occurred decrease of the urinary protein, but only the stage 2 and 3 was significant (p < 0.05). And the three stages had significant reduction of the mean blood pressure, too (p < 0.05). On the other hand there has a good correlation between the less proteinuria and the descent of the mean blood pressure in the stage I (r: 0.75, p < 0.05) and the stage 2 (r: 0.70, p < 0.05), but this did not occur in the stage 3 (r: 0.37, p < 0.1). No patient had raise serum potassium; neither did they have decrease glomerular filtration rate or anaemia.
  
  
  CONCLUSIONS
  The coadministration of Enalapril and Losartan was the most efficient treatment antiproteinuric effect. It was not only by the drug related reduction in systemic blood pressure. There weren't any adverse side effects in any patient dependent of the medication.
authors.affiliation: Unidad de Nefrología Infantil, Hospital General de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.
authors.forename: M
authors.initials: M
authors.lastname: Liern
authors.forename: S M
authors.initials: SM
authors.lastname: Dieguez
authors.forename: V
authors.initials: V
authors.lastname: De Reyes
authors.forename: G
authors.initials: G
authors.lastname: Vallejos
authors.forename: C
authors.initials: C
authors.lastname: Canepa
mesh_terms: D000293:Adolescent; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000502:physiology; D002648:Child; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000494:pharmacology*; D005260:Female; D006801:Humans; D019808:Losartan / Q000494:pharmacology*; D008297:Male; D011507:Proteinuria / Q000188:drug therapy*
chemical_list: D000959:Antihypertensive Agents; D004656:Enalapril; D019808:Losartan